{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T19:32:04Z","timestamp":1776108724696,"version":"3.50.1"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008457","name":"University of Virginia","doi-asserted-by":"publisher","award":["P30CA044579"],"award-info":[{"award-number":["P30CA044579"]}],"id":[{"id":"10.13039\/100008457","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004897","name":"European Organisation for Research and Treatment of Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011323","name":"African Fellowship Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011323","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006316","name":"Alliance for Clinical Trials in Oncology Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006316","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.lungcan.2026.109374","type":"journal-article","created":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T03:03:50Z","timestamp":1773457430000},"page":"109374","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["CHIO3: CHemotherapy combined with immune checkpoint inhibitor for operable stage IIIA\/B (N2) Non-Small cell lung cancer (AFT-46)"],"prefix":"10.1016","volume":"215","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7951-5677","authenticated-orcid":false,"given":"LW.","family":"Martin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"X.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8916-396X","authenticated-orcid":false,"given":"D.","family":"Kozono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Urbanic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1408-8229","authenticated-orcid":false,"given":"S.","family":"Graziano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Osarogiagbon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Mehran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Wain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Bestvina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JD.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3595-8011","authenticated-orcid":false,"given":"T.","family":"Stinchcombe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.lungcan.2026.109374_b0005","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jtho.2015.09.009","article-title":"The IASLC lung cancer Staging project: proposals for revision of the TNM Stage groupings in the forthcoming (eighth) edition of the TNM Classification for lung cancer","volume":"11","author":"Goldstraw","year":"2016","journal-title":"J. Thorac. Oncol."},{"issue":"24","key":"10.1016\/j.lungcan.2026.109374_b0010","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa1809697","article-title":"Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC","volume":"379","author":"Antonia","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.lungcan.2026.109374_b0015","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1016\/j.jtcvs.2018.10.140","article-title":"Survival benefits associated with surgery for advanced non-small cell lung cancer","volume":"157","author":"David","year":"2019","journal-title":"J. Thorac. Cardiovasc. Surg."},{"issue":"11","key":"10.1016\/j.lungcan.2026.109374_b0020","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S1470-2045(24)00498-4","article-title":"Perioperative chemotherapy and nivolumab in non-small-cell lung cancer (NADIM): 5-year clinical outcomes from a multicentre, single-arm, phase 2 trial","volume":"25","author":"Provencio","year":"2024","journal-title":"Lancet Oncol."},{"issue":"12","key":"10.1016\/j.lungcan.2026.109374_b0025","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1200\/JCO.21.01308","article-title":"Five-year survival outcomes from the PACIFIC trial: Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"40","author":"Spigel","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2026.109374_b0030","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ijrobp.2011.11.069","volume":"84","author":"Suntharalingam","year":"2012","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"9","key":"10.1016\/j.lungcan.2026.109374_b0035","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/j.jtho.2017.06.007","article-title":"Randomized phase II study of preoperative chemoradiotherapy \u00b1 panitumumab followed by consolidation chemotherapy in potentially operable locally advanced (stage IIIa, N2+) non-small cell lung cancer: NRG Oncology RTOG 0839","volume":"12","author":"Edelman","year":"2017","journal-title":"J. Thorac. Oncol."},{"issue":"5","key":"10.1016\/j.lungcan.2026.109374_b0040","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1016\/j.ijrobp.2009.01.069","article-title":"Preoperative chemotherapy versus preoperative chemoradiotherapy for stage III (N2) non-small-cell lung cancer","volume":"75","author":"Higgins","year":"2009","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"7","key":"10.1016\/j.lungcan.2026.109374_b0045","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/S1470-2045(08)70156-6","article-title":"Effect of preoperative chemoradiation in addition to preoperative chemotherapy: a randomised trial in stage III non-small-cell lung cancer","volume":"9","author":"Thomas","year":"2008","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2026.109374_b0050","doi-asserted-by":"crossref","unstructured":"Ripley RT, Suzuki K, Tan KS, et al. Postinduction positron emission tomography assessment of N2 nodes is not associated with ypN2 disease or overall survival in stage IIIA non-small cell lung cancer. J Thorac Cardiovasc Surg. 2016;151(4):969-977, 979.e1-3.","DOI":"10.1016\/j.jtcvs.2015.09.127"},{"issue":"6","key":"10.1016\/j.lungcan.2026.109374_b0055","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1093\/jnci\/djk093","article-title":"Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer","volume":"99","author":"van Meerbeeck","year":"2007","journal-title":"J. Natl Cancer Inst."},{"issue":"9687","key":"10.1016\/j.lungcan.2026.109374_b0060","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S0140-6736(09)60737-6","article-title":"Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial","volume":"374","author":"Albain","year":"2009","journal-title":"Lancet"},{"issue":"9998","key":"10.1016\/j.lungcan.2026.109374_b0065","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S0140-6736(15)60294-X","article-title":"Induction chemoradiation in stage IIIA\/N2 non-small-cell lung cancer: a phase 3 randomised trial","volume":"386","author":"Pless","year":"2015","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.lungcan.2026.109374_b0070","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1200\/JCO.2003.11.040","article-title":"Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trial","volume":"21","author":"Betticher","year":"2003","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109374_b0075","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/S1470-2045(21)00606-9","article-title":"Postoperative radiotherapy versus no postoperative radiotherapy in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 involvement (lung ART): an open-label, randomised, phase 3 trial","volume":"23","author":"Le Pechoux","year":"2022","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2026.109374_b0080","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.athoracsur.2017.02.031","article-title":"Surgically managed clinical stage IIIA\u2013clinical N2 lung cancer in the society of thoracic surgeons database","volume":"104","author":"Boffa","year":"2017","journal-title":"Ann. Thorac. Surg."},{"key":"10.1016\/j.lungcan.2026.109374_b0085","article-title":"Clinical outcomes with perioperative nivolumab (NIVO) by nodal status among patients (pts) with stage III resectable NSCLC: results from the phase 3 CheckMate 77T study","volume":"42(17_suppl):LBA8007-LBA8007","author":"Provencio","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.lungcan.2026.109374_b0090","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1056\/NEJMoa2215530","article-title":"Perioperative nivolumab and chemotherapy in stage III non-small-cell lung cancer","volume":"389","author":"Provencio","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.lungcan.2026.109374_b0095","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/jso.20644","article-title":"Nodal downstaging predicts survival following induction chemotherapy for stage IIIA (N2) non-small cell lung cancer in CALGB protocol #8935","volume":"94","author":"Jaklitsch","year":"2006","journal-title":"J. Surg. Oncol."},{"issue":"11","key":"10.1016\/j.lungcan.2026.109374_b0100","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/S1470-2045(20)30453-8","article-title":"Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial","volume":"21","author":"Provencio","year":"2020","journal-title":"Lancet Oncol."},{"issue":"21","key":"10.1016\/j.lungcan.2026.109374_b0105","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer","volume":"386","author":"Forde","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2026.109374_b0110","series-title":"In: World Conference for Lung Cancer 2025","article-title":"MA04.04Perioperative Pembrolizumab in Non-Small Cell Cancer (NSCLC): 4-Year Outcomes by Nodal Status in the KEYNOTE-671 Study","author":"Wakelee","year":"2025"},{"key":"10.1016\/j.lungcan.2026.109374_b0115","article-title":"Outcomes with perioperative durvalumab (D) in pts with resectable NSCLC and baseline N2 lymph node involvement (N2 R-NSCLC): an exploratory subgroup analysis of AEGEAN","volume":"42(16_suppl):8011\u20138011","author":"Heymach","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.lungcan.2026.109374_b0120","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1093\/jnci\/86.9.673","article-title":"A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer","volume":"86","author":"Roth","year":"1994","journal-title":"J. Natl Cancer Inst."},{"issue":"3","key":"10.1016\/j.lungcan.2026.109374_b0125","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1056\/NEJM199401203300301","article-title":"A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer","volume":"330","author":"Rosell","year":"1994","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.lungcan.2026.109374_b0130","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1016\/j.jtho.2019.04.005","article-title":"Real-world treatment of stage III NSCLC: the role of trimodality treatment in the era of immunotherapy","volume":"14","author":"Moore","year":"2019","journal-title":"J. Thorac. Oncol."},{"issue":"4","key":"10.1016\/j.lungcan.2026.109374_b0135","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/j.athoracsur.2016.04.058","article-title":"Surgical management of advanced non-small cell lung cancer is decreasing but is associated with improved survival","volume":"102","author":"David","year":"2016","journal-title":"Ann. Thorac. Surg."},{"key":"10.1016\/j.lungcan.2026.109374_b0140","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1117348","article-title":"Real-world clinical practice and outcomes in treating stage III non-small cell lung cancer: KINDLE-Asia subset","volume":"13","author":"Prabhash","year":"2023","journal-title":"Front. Oncol."},{"issue":"3","key":"10.1016\/j.lungcan.2026.109374_b0145","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.jtcvs.2018.05.059","article-title":"PACIFIC: Time for a surgical IIIA uprising","volume":"156","author":"Pass","year":"2018","journal-title":"J. Thorac. Cardiovasc. Surg."},{"issue":"6","key":"10.1016\/j.lungcan.2026.109374_b0150","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1016\/j.jtcvs.2023.09.029","article-title":"Induction chemoimmunotherapy with surgery versus concurrent chemoradiation followed by immunotherapy for stage III-N2 non-small cell lung cancer","volume":"167","author":"Kumar","year":"2024","journal-title":"J. Thorac. Cardiovasc. Surg."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109374_b0155","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/s43018-025-01104-z","article-title":"Clinical outcomes with perioperative nivolumab by nodal status in patients with stage III resectable NSCLC: phase 3 CheckMate 77T exploratory analysis","volume":"7","author":"Provencio","year":"2026","journal-title":"Nat Cancer."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226004356?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226004356?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T18:01:35Z","timestamp":1776103295000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500226004356"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":31,"alternative-id":["S0169500226004356"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109374","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CHIO3: CHemotherapy combined with immune checkpoint inhibitor for operable stage IIIA\/B (N2) Non-Small cell lung cancer (AFT-46)","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109374","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109374"}}